Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically ...
Oct 26 (Reuters) - The US health regulator has accepted Merck's experimental targeted drug for a priority review based on ...
A prospective 43-patient study found that diffusion tensor imaging parameters, especially fractional anisotropy, ...
An experimental drug from Merck & Co. helped women with advanced endometrial cancer live significantly longer than those ...
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial ...
Hazel B. Nichols, PhD, and Jama J. Brookes, MPH, discuss prediagnosis symptoms among endometrial cancer survivors, which may ...
A retrospective cohort study of more than 350,000 women with overweight or obesity found tirzepatide users had a lower hazard ...
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in ...
Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...
Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results